This Federal Grant Opportunity, issued by the National Cancer Institute (NCI), seeks R33 grant applications for the advanced development and validation of emerging technologies that can enhance molecular and cellular characterization of cancer. The funded projects must offer the potential to accelerate or improve research in areas such as cancer biology, early detection, diagnosis, treatment, epidemiology, and cancer health disparities. Key requirements include overcoming major feasibility gaps with supportive preliminary data, and focusing on technologies that advance the targeting, probing, or assessment of cancer-relevant molecular and cellular features. Proposals that merely apply existing technologies to new biological targets will not be considered. The application deadline is October 3, 2025.
The available funding for this opportunity is not explicitly stated, but the NCI typically awards grants ranging from $200,000 to over $1.6 million in total costs, with project periods of 2-5 years. The research must be conducted at the applicant's facilities in the United States, though some international collaboration is possible, particularly for clinical trials networks.
Generated 12/18/24, 6:13 AM